Patients with TP53 mutations have one of the worst prognosis in AML because their disease is both chemo and immune resistant, as shown by the poor response rate to standard treatments including intensive chemotherapy and hypomethylating agents and the high rate of relapse after allogeneic stem cell transplantation [91, 92, 93, 94]. This evidence concerns the gene TP53 and acute myeloid leukemia.